21IN - Platforms for tumour sequencing: Pertinence and practicability

Date 28 September 2014
Event ESMO 2014
Session Molecular profiling: Challenges and perspectives
Topics Drug Development
Pathology/Molecular Biology
Personalised Medicine
Presenter Martijn Lolkema
Citation Annals of Oncology (2014) 25 (suppl_4): iv9-iv10. 10.1093/annonc/mdu294
Authors M.P. Lolkema
  • Medical Oncology, University Hospital Utrecht, P.O. Box 85500 - Utrecht/NL

Abstract

Body

Abstract:

This presentation aims to provide an overview of why we need next generation sequencing platforms and how the different next generation sequencing platforms perform. Moreover, some data on implementation and outcome of the Dutch experience within the Center for Personalized Cancer Treatment will be discussed. One of the challenges of increased targeted treatment for cancer is to select our patients. Novel targeted therapies require an ever-increasing number of predictive biomarker determinations on the limited amount of tissue of patients with metastatic disease. This increasing demand for predictive biomarkers presents us with challenges in the realm of tissue availability, cost-effective use of diagnostics and limiting the time-to-proper diagnosis. Part of this challenge can be resolved by introducing the use of next generation sequencing techniques to multiplex genetic diagnostics. We show that we can validate and implement the "Ion Torrent" based technology for diagnostic purposes. We show that we can detect the mutations that are clinically actionable and that we widely broaden are ability to detect variants in well-known cancer genes. We also show that an improved version of the commercially available panel for the Ion Torrent is able to detect copy number changes reliably. This test represents an example of the type of multiplexed test we need for proper patient stratification in the near future. This will be supported by data derived from a cohort of about 700 cancer patients we tested. Furthermore this test can deliver interpretable data within a week as the interpretation of these data has been automated and requires only minimal hands-on intervention. Next generation sequencing for stratification of cancer patients for treatment will be implemented in the near-future to improve our ability to determine multiple genetic biomarkers in tumor tissue.

Disclosure:

M.P. Lolkema: I have received consultancy fees from Novartis, Roche, Amgen, GSK and BMS. I have received a research grant from Astellas.